(CNN) — A federal advisory committee on Tuesday voted overwhelmingly against of the use of MDMA, commonly known as ecstasy, as a treatment for post-traumatic stress disorder. The novel treatment has the potential to transform a field with significant need, but the committee had concerns about the integrity of the particular trials up for review. After hearing presentations from the US Food and Drug Administration, treatment sponsor Lykos Therapeutics and members of the public, the independent committee voted on recommendations to be made to the FDA.
Two of the 11 committee members said that they considered the treatment effective, while nine said that it was not. Only one committee member said that the benefits of the treatment outweigh the risks as presented, but the other 10 voted that they did not. Javascript is required for you to be able to read premium content.
Please enable it in your browser settings..
